Combined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.
Extracorporeal circulation (ECC) and hypothermia are used to maintain stable circulatory parameters and improve the ischemia tolerance of patients in cardiac surgery. However, ECC and hypothermia induce activation mechanisms in platelets and leukocytes, which are mediated by the platelet agonist ADP and the phosphoinositide-3-kinase (PI3K) p110β. Under clinical conditions these processes are associated with life-threatening complications including thromboembolism and inflammation. This study analyzes effects of ADP receptor P(2)Y(12) and P(2)Y(1) blockade and PI3K p110β inhibition on platelets and granulocytes during hypothermic ECC. Human blood was treated with the P(2)Y(12) antagonist 2-MeSAMP, the P(2)Y(1) antagonist MRS2179, the PI3K p110β inhibitor TGX-221, combinations thereof, or PBS and propylene glycol (controls). Under static in vitro conditions a concentration-dependent effect regarding the inhibition of ADP-induced platelet activation was found using 2-MeSAMP or TGX-221. Further inhibition of ADP-mediated effects was achieved with MRS2179. Next, blood was circulated in an ex vivo ECC model at 28°C for 30 minutes and various platelet and granulocyte markers were investigated using flow cytometry, ELISA and platelet count analysis. GPIIb/IIIa activation induced by hypothermic ECC was inhibited using TGX-221 alone or in combination with P(2)Y blockers (p<0.05), while no effect of hypothermic ECC or antiplatelet agents on GPIIb/IIIa and GPIbα expression and von Willebrand factor binding was observed. Sole P(2)Y and PI3K blockade or a combination thereof inhibited P-selectin expression on platelets and platelet-derived microparticles during hypothermic ECC (p<0.05). P(2)Y blockade alone or combined with TGX-221 prevented ECC-induced platelet-granulocyte aggregate formation (p<0.05). Platelet adhesion to the ECC surface, platelet loss and Mac-1 expression on granulocytes were inhibited by combined P(2)Y and PI3K blockade (p<0.05). Combined blockade of P(2)Y(12), P(2)Y(1) and PI3K p110β completely inhibits hypothermic ECC-induced activation processes. This novel finding warrants further studies and the development of suitable pharmacological agents to decrease ECC- and hypothermia-associated complications in clinical applications.
Department of Anesthesiology and Intensive Care Medicine, University of Tübingen, Tübingen, Germany. krajewski@thg-lab.de
Stefanie
S
Krajewski
Julia
J
Kurz
Tobias
T
Geisler
Karlheinz
K
Peter
Hans Peter
HP
Wendel
Andreas
A
Straub
D000244:Adenosine Diphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000704:Analysis of Variance; D006348:Cardiac Surgical Procedures / Q000379:methods*; D058534:Class I Phosphatidylinositol 3-Kinases; D004797:Enzyme-Linked Immunosorbent Assay; D005112:Extracorporeal Circulation / Q000009:adverse effects* / Q000379:methods; D005434:Flow Cytometry; D006801:Humans; D007036:Hypothermia, Induced / Q000009:adverse effects* / Q000379:methods; D066298:In Vitro Techniques; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology*; D008954:Models, Biological; D009025:Morpholines / Q000494:pharmacology; D019007:P-Selectin / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology*; D010976:Platelet Count; D058919:Purinergic P2 Receptor Antagonists / Q000494:pharmacology*; D011744:Pyrimidinones / Q000494:pharmacology
D009025:Morpholines; C111914:N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate; D019007:P-Selectin; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D011744:Pyrimidinones; C504718:TGX 221; D000244:Adenosine Diphosphate; D058534:Class I Phosphatidylinositol 3-Kinases; C497132:PIK3CB protein, human